Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst session for the stock in nearly four years. The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance,

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and diabetes treatments. LLY stock has delivered exponential returns from 2018 to mid-2024 of around 1,

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.

RFG Advisory LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 13.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission.

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and global expansion of sales of its diabetes and weight loss drugs should all add up to strong, 32% sales growth in the new year. The company forecasts 2025 sales of $58 billion to $61 billion.

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations.

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.